Literature DB >> 23311531

Allograft outcomes in outbred mice.

D K Reichenbach1, Q Li, R A Hoffman, A L Williams, W D Shlomchik, D M Rothstein, A J Demetris, F G Lakkis.   

Abstract

Inbreeding depression and lack of genetic diversity in inbred mice could mask unappreciated causes of graft failure or remove barriers to tolerance induction. To test these possibilities, we performed heart transplantation between outbred or inbred mice. Unlike untreated inbred mice in which all allografts were rejected acutely (6-16 days posttransplantation), untreated outbred mice had heterogeneous outcomes, with grafts failing early (<4 days posttransplantation), acutely (6-24 days) or undergoing chronic rejection (>75 days). Blocking T cell costimulation induced long-term graft acceptance in both inbred and outbred mice, but did not prevent the early graft failure observed in the latter. Further investigation of this early phenotype established that it is dependent on the donor, and not the recipient, being outbred and that it is characterized by hemorrhagic necrosis and neutrophilic vasculitis in the graft without preformed, high titer antidonor antibodies in the recipient. Complement or neutrophil depletion prevented early failure of outbred grafts, whereas transplanting CD73-deficient inbred hearts, which are highly susceptible to ischemia-reperfusion injury, recapitulated the early phenotype. Therefore, outbred mice could provide broader insight into donor and recipient determinants of allograft outcomes but their hybrid vigor and genetic diversity do not constitute a uniform barrier to tolerance induction. © Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Year:  2013        PMID: 23311531      PMCID: PMC3582712          DOI: 10.1111/ajt.12056

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  35 in total

Review 1.  The genetic basis of inbreeding depression.

Authors:  B Charlesworth; D Charlesworth
Journal:  Genet Res       Date:  1999-12       Impact factor: 1.588

2.  Murine equivalent of the human histo-blood group ABO gene is a cis-AB gene and encodes a glycosyltransferase with both A and B transferase activity.

Authors:  M Yamamoto; X H Lin; Y Kominato; Y Hata; R Noda; N Saitou; F Yamamoto
Journal:  J Biol Chem       Date:  2001-01-23       Impact factor: 5.157

3.  Neutrophils mediate parenchymal tissue necrosis and accelerate the rejection of complete major histocompatibility complex-disparate cardiac allografts in the absence of interferon-gamma.

Authors:  Masayoshi Miura; Tarek El-Sawy; Robert L Fairchild
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

Review 4.  Role of the complement system in rejection.

Authors:  Steven H Sacks; Paramit Chowdhury; Wuding Zhou
Journal:  Curr Opin Immunol       Date:  2003-10       Impact factor: 7.486

5.  Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections.

Authors:  Michael A Brehm; Thomas G Markees; Keith A Daniels; Dale L Greiner; Aldo A Rossini; Raymond M Welsh
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

6.  Genealogies of mouse inbred strains.

Authors:  J A Beck; S Lloyd; M Hafezparast; M Lennon-Pierce; J T Eppig; M F Festing; E M Fisher
Journal:  Nat Genet       Date:  2000-01       Impact factor: 38.330

7.  Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells.

Authors:  F Kissmeyer-Nielsen; S Olsen; V P Petersen; O Fjeldborg
Journal:  Lancet       Date:  1966-09-24       Impact factor: 79.321

8.  Local synthesis of complement component C3 regulates acute renal transplant rejection.

Authors:  Julian R Pratt; Shamim A Basheer; Steven H Sacks
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

Review 9.  Of mice and not men: differences between mouse and human immunology.

Authors:  Javier Mestas; Christopher C W Hughes
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

10.  Heterologous immunity provides a potent barrier to transplantation tolerance.

Authors:  Andrew B Adams; Matthew A Williams; Thomas R Jones; Nozomu Shirasugi; Megan M Durham; Susan M Kaech; E John Wherry; Thandi Onami; J Gibson Lanier; Kenneth E Kokko; Thomas C Pearson; Rafi Ahmed; Christian P Larsen
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

View more
  6 in total

Review 1.  Lessons and limits of mouse models.

Authors:  Anita S Chong; Maria-Luisa Alegre; Michelle L Miller; Robert L Fairchild
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

2.  Getting Down and Dirty: Germ-Exposed Laboratory Mice as a Model of the Adult Human Immune System.

Authors:  Roger Tieu; Fadi G Lakkis; Martin H Oberbarnscheidt
Journal:  Transplantation       Date:  2016-12       Impact factor: 4.939

Review 3.  Evolving Approaches in the Identification of Allograft-Reactive T and B Cells in Mice and Humans.

Authors:  James S Young; Christine McIntosh; Maria-Luisa Alegre; Anita S Chong
Journal:  Transplantation       Date:  2017-11       Impact factor: 4.939

Review 4.  Experimental models of cardiac transplantation: design determines relevance.

Authors:  William M Baldwin; Charles A Su; Thomas M Shroka; Robert L Fairchild
Journal:  Curr Opin Organ Transplant       Date:  2014-10       Impact factor: 2.640

5.  Spontaneous Transformation of Murine Oviductal Epithelial Cells: A Model System to Investigate the Onset of Fallopian-Derived Tumors.

Authors:  Michael P Endsley; Georgette Moyle-Heyrman; Subbulakshmi Karthikeyan; Daniel D Lantvit; David A Davis; Jian-Jun Wei; Joanna E Burdette
Journal:  Front Oncol       Date:  2015-07-17       Impact factor: 6.244

6.  Generation and selection of pluripotent stem cells for robust differentiation to insulin-secreting cells capable of reversing diabetes in rodents.

Authors:  Sheryl M Southard; Rama P Kotipatruni; William L Rust
Journal:  PLoS One       Date:  2018-09-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.